Factors affecting antibody response of newborns to repeated administrations of the rotavirus vaccine RIT 4237.
The safety and immunogenicity of repeated doses of RIT 4237, an oral live attenuated rotavirus vaccine of bovine origin, as well as the influence of gastric acidity and maternal antibodies on the vaccine "take rate" were studied in newborns. The vaccine was given orally on the first day of life, at 1 month, and at 2 months of age. Fifty-seven newborns entered the study but only 36 completed the trial. No adverse reaction was observed after vaccination. Immune responses were evaluated by titrating pre- and postvaccination serum antibodies to RIT 4237 by a neutralization technique. Eight of 43 (18.6%) tested infants responded to the first dose of vaccine. Subsequently another six and 11 infants responded to the second and third dose, respectively. The total cumulative response after the third dose was 23 of 36 vaccinees (63.9%). The geometric mean neutralizing antibody titers was lower in responders than in nonresponders before the first dose of vaccine indicating that maternal antibodies interfered with vaccine "take." Since the RIT 4237 strain is acid sensitive, gastric pH was measured at the time of each vaccination. Mean pH values in responders were not significantly different than those found in nonresponders. Therefore, vaccine failures cannot be due to inactivation of the rotavirus vaccine in the stomach but instead they can be attributed to high levels of maternal antibodies. At each vaccination, additional subjects seroconverted. Therefore, a multiple dose scheme is advisable to obtain an optimal immune response.
Cadranel
S
S
Department of Virology, University of Brussels, Belgium.
Zeglache
S
S
Jonckheer
T
T
Zissis
G
G
Andre
F E
FE
Bogaerts
H
H
Delem
A
A
D000284:Administration, Oral; D000914:Antibodies, Viral / Q000032:analysis*; D005745:Gastric Acidity Determination; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007117:Immunization, Secondary; D007223:Infant; D007231:Infant, Newborn; D009500:Neutralization Tests; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated / Q000008:administration & dosage* / Q000009:adverse effects; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects
D000914:Antibodies, Viral; C041165:RIT 4237 vaccine; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated; D014765:Viral Vaccines